The best peptide for fat loss is tirzepatide when the goal is substantial overall fat and weight reduction. Tesamorelin stands out for visceral abdominal fat, while CJC-1295 + ipamorelin is better suited to body recomposition, recovery, and lean-mass support. MOTS-c and AOD-9604 focus more specifically on metabolic and fat-mobilization pathways.
Fat loss is not exactly the same as weight loss. Scale weight includes fat, muscle, water, glycogen, and the contents of the digestive tract. A successful fat-loss plan aims to reduce fat mass while preserving strength and useful lean tissue.
Here is how the leading fat-loss peptides compare and how to match them to your goal.
Tirzepatide is the strongest overall option for people who want significant fat and weight loss. It activates GIP and GLP-1 receptors, two pathways involved in appetite, glucose control, and energy intake.
In the SURMOUNT-1 trial, tirzepatide produced average body-weight reductions of up to 20.9% over 72 weeks. A DXA substudy then looked directly at body composition and found that tirzepatide reduced fat mass by 33.9% compared with 8.2% with placebo. Approximately three-quarters of the weight lost was fat mass.
Tirzepatide supports fat loss by helping people:
It is best for people whose primary barrier is appetite or the difficulty of maintaining the nutrition plan long enough to see meaningful results.
The goal during tirzepatide-assisted weight loss is to keep the fat-loss signal high while protecting muscle. Prioritize protein-rich meals, resistance training, daily movement, and a calorie deficit that supports rather than drains your training.
Tesamorelin is a growth hormone-releasing hormone analog with a particularly strong connection to visceral adipose tissue—the deep abdominal fat stored around internal organs.
Unlike general scale-weight treatments, tesamorelin is primarily a body-composition peptide. In a randomized controlled trial of adults with abdominal obesity and reduced GH secretion, tesamorelin selectively reduced visceral fat and improved triglycerides and inflammatory markers.
Clinical trials in people with HIV-associated abdominal-fat accumulation also found reductions in visceral fat, trunk fat, and waist circumference. A recent meta-analysis reported reduced visceral and liver fat alongside increased lean body mass in that studied population.
Tesamorelin is most relevant when the goal is:
Read our guide to tesamorelin benefits and learn whether running burns visceral fat.
CJC-1295 + ipamorelin is better described as a body-recomposition and recovery combination than a direct appetite treatment.
The two peptides support growth hormone release through complementary pathways:
In controlled human research, CJC-1295 produced sustained increases in growth hormone and IGF-1. These signals participate in fat metabolism, tissue repair, protein metabolism, and body-composition regulation.
CJC-1295 + ipamorelin may fit a fat-loss plan when the priorities include:
This pairing works around the habits that drive fat loss. It does not directly suppress appetite like tirzepatide, making it more relevant for people who can manage calorie intake but want stronger recovery and recomposition support.
Learn more about CJC-1295 and ipamorelin and the best peptides for muscle growth.
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA. It acts as a metabolic signal and is studied in relation to glucose handling, AMPK activation, skeletal muscle, and exercise adaptation.
Foundational research found that MOTS-c regulated metabolic homeostasis and insulin sensitivity in experimental models. Its main target appeared to be skeletal muscle, a major site for glucose disposal and energy use.
MOTS-c is relevant to a fat-loss plan because it may support:
Think of MOTS-c as an energy and metabolism peptide rather than a direct appetite suppressant. It makes the most sense for people combining fat loss with regular exercise and metabolic-health goals.
Our guide to peptides for energy explains how MOTS-c compares with GH- and focus-oriented peptides.
AOD-9604 is a modified fragment based on amino acids 176–191 of human growth hormone. It was designed to focus on the fat-metabolism portion of the GH molecule without reproducing the full range of growth-hormone activity.
AOD-9604 is commonly discussed for:
Its most natural role is as part of a combined body-composition protocol rather than as the only tool in a large weight-loss plan. Bowery Clinic includes AOD-9604 in Form, where it is paired with tesamorelin, ipamorelin, and MOTS-c to address visceral fat, GH signaling, metabolism, and energy from multiple directions.
Form is designed for people seeking body-composition support without choosing one pathway at a time.
The formula combines:
This combination makes Form especially relevant to people who want:
Tirzepatide remains the stronger choice when appetite and substantial total weight loss are the main goals. Form is more body-composition oriented and aligns naturally with strength training, cardio, and a high-protein nutrition plan.
Losing 15 pounds is not automatically better than losing 10. The result depends on how much came from fat versus muscle, water, and glycogen.
A higher-quality fat-loss phase aims for:
Tirzepatide is powerful for total weight and fat loss. Tesamorelin is more selective for visceral fat. CJC-1295 + ipamorelin and MOTS-c fit the recovery, metabolic, and lean-mass side of the plan.
This distinction is why there is no single best peptide for every body-composition goal.
“Belly fat” can refer to two different tissues:
Tesamorelin is the most specifically aligned with visceral fat. Tirzepatide is best for reducing overall fat mass, which can include both abdominal and non-abdominal stores.
You cannot spot-reduce subcutaneous fat from one area. The most effective strategy combines total fat loss, regular exercise, and patience with individual fat-distribution patterns.
The best cutting peptide depends on the main challenge.
A successful cut keeps resistance-training intensity high, protein adequate, and the deficit moderate enough to preserve performance.
Simultaneously losing fat and building muscle is called body recomposition. It is most achievable for newer lifters, people returning after time away, and those with enough stored body fat to support a calorie deficit.
CJC-1295 + ipamorelin is the most directly recovery-oriented peptide combination for recomp. Tirzepatide can create powerful fat loss, while Form combines metabolic, visceral-fat, and GH-related pathways.
For the training side of recomposition:
The scale may move slowly while the waist shrinks and strength improves. That is often a better body-composition outcome than rapid weight loss with falling gym performance.
The SURMOUNT-1 body-composition substudy found that approximately 75% of weight lost with tirzepatide came from fat mass and 25% from lean mass. This makes lean-mass preservation an important part of any significant weight-loss plan.
Use these fundamentals:
Build each meal around a meaningful protein source. Protein supports muscle repair, satiety, and recovery during a calorie deficit.
Strength training tells the body that muscle remains useful. Continue lifting challenging weights rather than replacing all training with cardio.
Faster is not always better. A manageable rate of loss makes it easier to train, recover, and meet protein needs.
Poor sleep can increase hunger and reduce training quality. It also undermines the recovery environment that CJC-1295, ipamorelin, and similar peptides are intended to support.
Track waist circumference, strength, progress photos, and clothing fit. Body-composition improvements may be clearer there than on the scale.
The timeline depends on the peptide and the outcome.
Use averages rather than daily fluctuations. Compare weekly weight averages and monthly waist measurements under similar conditions.
Tirzepatide is the best overall choice for substantial fat and weight loss. Tesamorelin is the most specific option for visceral abdominal fat, while Form supports fat loss and body recomposition through multiple pathways.
Tirzepatide has the strongest human outcome data for reducing total fat mass. In a SURMOUNT-1 substudy, fat mass decreased by 33.9% over 72 weeks.
Tesamorelin has the clearest specific connection to visceral-fat reduction. It supports endogenous growth-hormone signaling through the GHRH receptor.
AOD-9604 is designed around growth hormone's fat-mobilization region and is commonly used as part of a combined cutting or body-composition plan. Bowery Clinic includes it in the Form blend.
Yes, when paired with progressive resistance training and adequate protein. CJC-1295 + ipamorelin supports recovery and lean-mass goals, while tirzepatide, tesamorelin, or Form can address the fat-loss side.
The leading options discussed here are not conventional stimulants. Tirzepatide regulates appetite through incretin receptors; tesamorelin and CJC-1295 influence GH signaling; MOTS-c acts through metabolic pathways.
Tirzepatide is the best overall peptide for substantial fat loss. Tesamorelin is the leading option for visceral abdominal fat, CJC-1295 + ipamorelin supports recomp and recovery, and MOTS-c supports metabolic and exercise pathways. Form combines several of these goals in one clinician-guided protocol.
Explore Bowery Clinic's tirzepatide, tesamorelin, or Form programs and complete a clinician review to build a focused fat-loss and body-composition plan.
